Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$43.35 USD
+0.59 (1.38%)
Updated May 30, 2024 04:00 PM ET
After-Market: $43.35 0.00 (0.00%) 7:02 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.35 USD
+0.59 (1.38%)
Updated May 30, 2024 04:00 PM ET
After-Market: $43.35 0.00 (0.00%) 7:02 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval
by Zacks Equity Research
Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
by Zacks Equity Research
Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.
Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for Xofluza to prevent influenza in people 12 years of age and older following contact with someone with influenza.
Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy
by Zacks Equity Research
Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.
Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate
by Zacks Equity Research
Gilead (GILD) announces successful top-line results from a phase I/II study on its investigational, long-acting HIV-1 capsid inhibitor.
Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study
by Zacks Equity Research
Kodiak Sciences (KOD) completes recruitment in the pivotal phase IIb/III DAZZLE study, currently evaluating KSI-301 for the treatment of patients with wet age-related macular degeneration.
Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed
by Zacks Equity Research
Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.
J&J (JNJ) Seeks Label Expansion of Darzalex Faspro Combination
by Zacks Equity Research
J&J (JNJ) files regulatory application in the United States and Europe seeking label expansion of Darzalex Faspro in combination with pomalidomide and dexamethasone for treating multiple myeloma.
Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.
Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut
by Zacks Equity Research
Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.
Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.
Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus
by Zacks Equity Research
Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.
Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.
ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y
by Zacks Equity Research
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.
Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises
by Zacks Equity Research
Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis
by Zacks Equity Research
J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.
Halozyme Therapeutics (HALO) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More
by Kinjel Shah
Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.